Immuneering rises on orphan drug designation for treatment of pancreatic cancer

by
Contributor since / Followers

1 month ago

Immuneering Corporation (NASDAQ:IMRX) shares up 24.5% premarket after it announced that the U.S. FDA has granted orphan drug designation to IMM-1-104 in the treatment of pancreatic cancer.
IMM-1-104 is currently being evaluated in a Phase 2a clinical trial in patients with advanced solid tumors, including pancreatic cancer.
Source: Press Release

Tags: TEVA